ResMed stock (US7611521078): Ex-dividend date arrives May 14 amid CEO option exercise

ResMed Inc heads into ex-dividend trading on May 14, 2026, with a $0.60 quarterly payout, as CEO Mick Farrell exercised stock options during recent NYSE price pressure.

ResMed Inc goes ex-dividend on May 14, 2026, with a quarterly dividend of $0.60 per share payable on June 18 to shareholders of record, according to ad-hoc-news.de as of May 14, 2026. This comes as CEO Mick Farrell exercised stock options amid a recent NYSE share price drop, per ad-hoc-news.de as of May 14, 2026. Shares traded at $203.79 on May 12, up 2.53%, according to ad-hoc-news.de as of May 14, 2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: ResMed Inc.
• Sector/industry: Medical devices / Respiratory care
• Headquarters/country: United States
• Core markets: US, Europe, Asia-Pacific
• Key revenue drivers: Sleep apnea devices, masks, ventilators
• Home exchange/listing venue: NYSE (RMD)
• Trading currency: USD

ResMed Inc.: core business model

ResMed Inc. develops, manufactures and distributes medical devices for treating sleep-disordered breathing, chronic obstructive pulmonary disease (COPD) and other respiratory conditions. The company focuses on connected health solutions including CPAP machines, masks and ventilators. Its portfolio targets the growing sleep apnea market, with products like the AirSense and AirCurve series. ResMed generates revenue primarily from device sales and recurring consumables such as masks and filters.

The business model emphasizes SaaS-like services through myAir app for patient adherence tracking, appealing to US healthcare providers and insurers. ResMed holds a leading position in the US market, where sleep apnea affects over 30 million adults, supporting its relevance for American investors tracking medtech innovation.

Main revenue and product drivers for ResMed Inc.

ResMed's top revenue driver is its sleep and respiratory care segment, which accounted for the majority of sales in recent quarters. Mask and consumables contribute steady recurring revenue, while new device launches drive growth. In early 2026, the company reported quarterly revenue of US$1.29 billion, up 11% year-over-year, with operating income rising 22%, per Motley Fool Australia as of May 14, 2026.

Device sales have accelerated amid competitor Philips' recall issues, bolstering ResMed's market share in the US, its largest market. Dividend payouts like the upcoming $0.60 quarterly distribution underscore cash flow strength from these drivers.

Industry trends and competitive position

The sleep apnea device market is expanding due to rising obesity rates and awareness in the US, with ResMed commanding significant share alongside Philips Respironics and Fisher & Paykel. Digital health integration positions ResMed favorably as payers prioritize adherence data. Recent share price gains to $203.79 on May 12 reflect this momentum on NYSE.

Why ResMed Inc. matters for US investors

Listed on NYSE, ResMed offers US investors exposure to the $8 billion-plus US sleep diagnostics market. Its strong balance sheet and dividend yield attract income-focused portfolios, while growth in connected devices aligns with telehealth trends post-COVID.

Conclusion

ResMed Inc. approaches its May 14, 2026 ex-dividend date with a solid $0.60 payout, complemented by CEO option exercises amid volatile NYSE trading. The company's leadership in respiratory devices and recent revenue growth highlight its stability in medtech. US investors monitor these developments as market dynamics and insider activity shape near-term sentiment.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.